Publications by authors named "A Fader"
In the field of gynecologic cancer, low-grade serous ovarian cancer (LGSOC) has been poorly understood and underinvestigated until recently. Similarly, understanding of the distinct properties and therapeutic sensitivities of gynecologic melanoma and cervical neuroendocrine tumors has recently accelerated. For each of these rare cancers, we explore the epidemiology and natural history, discuss the prognosis, diagnostic testing, and contemporary molecular classification, and then deliberate existing and emerging therapeutic strategies.
View Article and Find Full Text PDFRecent advances in molecular analyses of ovarian cancer have revealed a wealth of promising tumour-specific biomarkers, including protein, DNA mutations and methylation; however, reliably detecting such alterations at satisfactorily high sensitivity and specificity through low-cost methods remains challenging, especially in early-stage diseases. Here we present PapDREAM, a new approach that enables detection of rare, ovarian-cancer-specific aberrations of DNA methylation from routinely-collected cervical Pap specimens. The PapDREAM approach employs a microfluidic platform that performs highly parallelized digital high-resolution melt to analyze locus-specific DNA methylation patterns on a molecule-by-molecule basis at or near single CpG-site resolution at a fraction (< 1/10th) of the cost of next-generation sequencing techniques.
View Article and Find Full Text PDFArticle Synopsis
- Treatment for recurrent ovarian clear cell carcinoma (OCCC) is challenging due to low chemotherapy response rates and high recurrence rates, but immunotherapy shows promise, specifically with pembrolizumab combined with bevacizumab and/or cyclophosphamide.
- A study of four patients revealed that those treated with this combination experienced durable partial responses lasting 6 to 15 months, with some patients having specific genetic mutations that may influence treatment outcomes.
- While the combination therapy appears effective, two patients faced serious side effects, highlighting the need for careful monitoring and further studies to confirm these findings.
Dedifferentiated endometrial carcinoma is a rare, highly aggressive subtype of endometrial cancer associated with poor survival outcomes. Current guidelines recommend treatment of advanced-stage disease with surgical staging or cytoreduction and platinum/taxane-based chemotherapy. Despite these approaches, the achievement of long-term remission or prolonged survival is challenging.
View Article and Find Full Text PDF